• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

    5.550 +0.230 (+4.32%)
    Delayed Quote Updated: 3:42 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about AN2 Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
    Via AB Newswire
    News headline image
    AN2 Therapeutics Announces $40 Million Private Placement Financing
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.